
Importance Chronic rhinosinusitis (CRS) is common, yet one-third of patients do not achieve clinically meaningful improvement after endoscopic sinus surgery (ESS). Existing preoperative measures capture only a portion of the prognostic landscape, and no tool integrates patient-reported phenotype, symptom severity, and objective imaging into a single ordinal index for surgical prognosis. Objective To develop a CRS Severity Index (CRS-SI) that integrates patient-reported symptom phenotypes, characterized across symptom duration categories, with objective imaging measures to estimate the probability of clinically meaningful improvement after ESS. Design, Setting, and Participants Prospective cohort study with longitudinal data collected from academic tertiary care rhinology clinics between January 2020 and May 2025; follow-up was assessed at 3, 6, and 12 months after surgery. Participants were consecutive patients with CRS aged 16 to 95 years for whom medical management failed and who underwent ESS. Exposures Baseline 22-item Sino-Nasal Outcome Test (SNOT-22) measures, symptom phenotype dimensions derived from multiple correspondence analysis, polyp status, Lund-Mackay, and Lund-Kennedy scores. Main Outcomes and Measures The primary outcome was clinically meaningful improvement, defined as SNOT-22 improvement of at least 8.9 points from baseline to follow-up. Seven candidate predictors were organized into clinical (baseline SNOT-22, latent symptom phenotype dimensions, polyp status) and imaging (Lund-Mackay, Lund-Kennedy, frontal opacification) arms. CRS-SI was derived using sequential sequestration and conjunctive consolidation. Results Of 488 eligible patients with at least 1 postoperative SNOT-22, 450 with complete clinical and imaging grading data comprised the analytic cohort. Among 450 patients (mean [SD] age, 55.5 [16.3] years; 54.7% [246 of 450] male), 64% achieved clinically meaningful improvement. Of 7 candidate predictors, 6 met bivariate screening criteria (rank-biserial |r|≥0.1 with 95% CI excluding 0). Sequential sequestration selected baseline SNOT-22 severity and a headache and/or chemosensory–dominant symptom phenotype as clinical classifiers, and Lund-Mackay and Lund-Kennedy scores as imaging classifiers. The 4-grade CRS-SI produced a monotonic improvement gradient (grade 1, 81% [95% CI, 72%-88%] to grade 4, 29% [95% CI, 19%-40%]), with a risk difference of 52.5 (95% CI, 39.3-65.7) percentage points between best and worst grades. Discrimination was moderate (C statistic, 0.692; 95% CI, 0.643-0.740) and exceeded imaging grading alone; bootstrap calibration slope, 1.00 (95% CI, 0.77-1.31). Performance was consistent across CRS phenotypes and time points. Conclusions and Relevance In this study, a 4-level CRS Severity Index integrating patient-reported symptom profiles with computed tomography and endoscopic imaging stratified improvement after ESS across a 52 percentage–point gradient. If validated externally, the CRS-SI may support preoperative counseling and clinical trial stratification.
Importance Chronic rhinosinusitis (CRS) symptom duration has not been associated with distinct patterns of symptom co-occurrence, limiting its utility for clinical phenotyping and treatment planning. Patients with longer-standing CRS may represent biologically or treatment-modified presentations, but it remains unclear whether symptom patterns differ systematically by duration. Objective To characterize symptom phenotypes based on CRS symptom duration and determine whether patterns of symptom co-occurrence differ systematically across duration categories. Design, Setting, and Participants A cross-sectional analysis of prospectively collected data in a large CRS cohort including patients in academic tertiary care center rhinology clinics aged 11 to 85 years with CRS who in whom appropriate medical therapy was not successful, met criteria, and underwent endoscopic sinus surgery between January 1, 2020, and May 1, 2025. Main Outcomes and Measures Binary sinonasal symptom indicators from a structured symptom checklist were analyzed using multiple correspondence analysis (MCA) to identify latent patterns of symptom co-occurrence. Dimension scores were then compared across duration categories (<6 months, 6 months to 3 years, >3 years) using Kruskal-Wallis tests with post hoc Dunn testing. As convergent evidence, the 22-item Sino-Nasal Outcome Test (SNOT-22) total and subdomain scores were compared across the same duration groups. Results Among 661 patients (mean [SD] age, 54.4 [16.7] years; 364 [55.1%] male; 85 [12.9%] Black and 289 [43.7%] Hispanic), MCA of 21 binary sinonasal symptom indicators identified 3 principal dimensions, explaining 40% of total variance. Dimension 1 reflected global symptom burden and increased monotonically with symptom duration (ε 2 = 0.035; 95% CI, 0.017-1.000). Dimension 2 captured a phenotypic shift between headache or pressure–dominant and chemosensory or drainage–dominant symptom patterns and varied across duration groups (ε 2 = 0.025; 95% CI, 0.012-1.000). Dimension 3 captured airway-irritative and sensory features and varied across duration groups (ε 2 = 0.019; 95% CI, 0.007-1.000), with post hoc testing showing separation between the 2 longer-duration groups. SNOT-22 total and subdomain scores replicated this threshold pattern across duration cohorts. Conclusions and Relevance This study found that, in medically refractory CRS, the duration of symptoms was associated with structural differences in symptom phenotypes rather than simple, linear increases in symptom severity. Early chronic disease (<6 months) is characterized by a lower overall symptom burden and headache/pressure predominance. Longer disease duration is associated with greater total symptom load and a predominance of chemosensory dysfunction and drainage-dominant concerns. Additional longitudinal validation of these phenotypic patterns and their association with clinical response is needed.
The Viewpoint advocates for updates to newborn hearing screening recommendations to include automated auditory brainstem response testing to determine candidacy for otoferlin ( OTOF ) gene therapy.